Results 91 to 100 of about 1,361 (136)

Proapoptotic activity of JNK-sensitive BH3-only proteins underpins ovarian cancer response to replication checkpoint inhibitors. [PDF]

Mol Cancer
Venkatachalam A, Correia C, Peterson KL, Hou X, Schneider PA, Strathman AR, Flatten KS, Sine CC, Balczewski EA, McGehee CD, Larson MC, Duffield LN, Meng XW, Vincelette ND, Ding H, Oberg AL, Couch FJ, Swisher EM, Li H, Weroha SJ, Kaufmann SH.   +20 more
europepmc   +1 more source

Esophageal Cancer Cells Exhibit Heterogeneity in DNA Double-Strand Break Repair and G2/M Checkpoint Arrest Associated With Cell Viability After Ionizing Radiation. [PDF]

Adv Radiat Oncol
Tateno K, Okuda K, Haruna S, Isono M, Ishikawa T, Okumura H, Hayashi R, Suzuki R, Takahashi T, Saito T, Yokobori T, Uchihara Y, Suzuki K, Yamauchi M, Shirabe K, Saeki H, Shibata A.   +16 more
europepmc   +1 more source

Sequencing PARP inhibitors in breast cancer: lessons learned and emerging insights. [PDF]

NPJ Breast Cancer
Aloss K, Frederick MI, Hassan S.
europepmc   +1 more source

Personalized Drug Screening and Risk Assessment in Patient-Derived Gastroenteropancreatic Neuroendocrine Neoplasms.

J Clin Endocrinol Metab
Auernhammer CJ, Wang K, Maccio U, Knösel T, Hungbauer MP, Schilbach K, Maurer J, Peischer L, Reul A, Kuzmenko E, Luca E, Hamati J, Vetter D, Oberholzer J, Fritsch R, Pacak K, Grossman AB, Beuschlein F, Reincke M, Hantel C, Zitzmann K, Nölting S.   +21 more
europepmc   +1 more source

Preclinical NCI-MPACT: prospective modeling of the mutation-based NCI-MPACT clinical trial therapeutic strategy in patient-derived xenograft models. [PDF]

Front Oncol
Evrard YA, Alcoser SY, Mullendore M, Chen L, Lih CJ, Kannan VR, Datta V, Dutko L, Jiwani S, Rubinstein LV, Zhao Y, Williams PM, Palmisano A, Kuhlmann L, Simpson M, Kummar S, Das B, Karlovich C, Polley E, Li MC, Chen AP, Hollingshead MG, Doroshow JH.   +22 more
europepmc   +1 more source

Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy. [PDF]

Cancer Discov
Dias MH, Friskes A, Wang S, Fernandes Neto JM, van Gemert F, Mourragui S, Papagianni C, Kuiken HJ, Mainardi S, Alvarez-Villanueva D, Lieftink C, Morris B, Dekker A, van Dijk E, Wilms LHS, da Silva MS, Jansen RA, Mulero-Sánchez A, Malzer E, Vidal A, Santos C, Salazar R, Wailemann RAM, Torres TEP, De Conti G, Raaijmakers JA, Snaebjornsson P, Yuan S, Qin W, Kovach JS, Armelin HA, Te Riele H, van Oudenaarden A, Jin H, Beijersbergen RL, Villanueva A, Medema RH, Bernards R.   +37 more
europepmc   +1 more source

Efficacy and Biomarker Analysis of Adavosertib in Differentiated Thyroid Cancer [PDF]

Cancers, 2021
Differentiated thyroid cancer (DTC) patients are usually known for their excellent prognoses. However, some patients with DTC develop refractory disease and require novel therapies with different therapeutic mechanisms. Targeting Wee1 with adavosertib has emerged as a novel strategy for cancer therapy.
Richard Wong, Shu-Fu Lin, Ting-Chao Chou   +2 more
exaly   +4 more sources

Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing Cancers [PDF]

Clinical Cancer Research, 2023
Abstract Purpose: Cyclin E (CCNE1) has been proposed as a biomarker of sensitivity to adavosertib, a Wee1 kinase inhibitor, and a mechanism of resistance to HER2-targeted therapy. Experimental Design: Copy number and ...
Funda Meric-Bernstam, Jaffer A Ajani, Siqing Fu   +2 more
exaly   +4 more sources

Effect of food on the pharmacokinetics of the WEE1 inhibitor adavosertib (AZD1775) in patients with advanced solid tumors [PDF]

Cancer Chemotherapy and Pharmacology, 2020
Abstract Purpose To support future dosing recommendations, the effect of food on the pharmacokinetics of adavosertib, a first-in-class, small-molecule reversible inhibitor of WEE1 kinase, was assessed in patients with advanced solid tumors. Methods In this Phase I, open-label, randomized, two-period, two-sequence crossover study, the pharmacokinetics
Alain Ravaud, Patricia Roxburgh, Ganesh Mugundu   +2 more
exaly   +7 more sources

Pediatric phase 2 trial of a WEE1 inhibitor, adavosertib (AZD1775), and irinotecan for relapsed neuroblastoma, medulloblastoma, and rhabdomyosarcoma [PDF]

Cancer, 2023
AbstractBackgroundInhibition of the WEE1 kinase by adavosertib (AZD1775) potentiates replicative stress from genomic instability or chemotherapy. This study reports the pediatric solid tumor phase 2 results of the ADVL1312 trial combining irinotecan and adavosertib.MethodsPediatric patients with recurrent neuroblastoma (part B), medulloblastoma/central
Kristina Cole
exaly   +5 more sources